India · Delayed Price · Currency is INR Blue Jet Healthcare Earnings Call Transcripts
Fiscal Year 2027
-
Q1 FY27 revenue rose 25% QoQ to INR 293 crore, with EBITDA of INR 98 crore and improved operating margin. API recovery and strategic investment support the outlook, while raw-material inflation and transit timing remain uncertainties.
Fiscal Year 2026
-
FY 2026 revenue fell 8% as PI/API destocking offset strong contrast media growth. FY 2027 visibility is improving, with double-digit contrast media growth expected, while major capacity investments and uncertain logistics costs shape the outlook.
-
Q3 revenue fell 40% YoY amid destocking, mix effects and one-time costs, while 9M revenue rose 3%. FY27 growth plans center on new contrast media capacity, backward integration and the CDMO pipeline, but recovery timing remains uncertain.
-
H1 FY26 revenue rose 40% YoY, while PAT grew 36% and EBITDA rose 41%. Q2 revenue recognition and margins were distorted by delayed contrast-media shipments; expansion plans and customer demand visibility remain strong.
-
Q1 revenue rose 118% YoY, while gross margin fell to 48.5% amid inventory drawdown and product mix; management cited ~53% as the normalized level for the current portfolio. Capacity expansion, new launches and a growing CDMO pipeline underpin FY26 confidence.
Fiscal Year 2025
-
FY2025 delivered record revenue, EBITDA and PAT, with strong PI/API growth and improved margins. Capacity investment, new molecule launches and CDMO demand support expansion, while contrast media timing and working-capital needs remain watchpoints.
-
Q3 revenue rose 91% YoY to INR 3,184m and PAT climbed 208% to INR 990m, with new capacity driving growth. Near-term demand is encouraging, while Unit 3 commercialization is now expected in H2 FY26 and R&D investment is expanding.
-
Q1 revenue fell 11% QoQ as Red Sea delays deferred contrast-media sales recognition, despite higher production and dispatches. New capacity, customer-backed demand and a broad pipeline underpin expansion plans.